Clinical trials: Carcinoma of Prostate
Prostatic Neoplasms, Castration-Resistant
A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer
The purpose of this real-world study is to learn about the effects of 2 study medicines called enzalutamide and abiraterone used to treat metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT05968599
- Testing
- Enzalutamide, Abiraterone acetate
- Where
- United States
- Volunteers
- 2,731 people
- Sponsor
- Pfizer
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC
The purpose of this study was to assess the efficacy, safety, tolerability, Pharmacokinetic(s) (PK) and dosimetry of [177Lu]Lu-PSMA-617 when administered in addition to Best Supportive/Best Standard of Care (BSC/BSoC) in Chinese…
- Trial name
- NCT05670106
- Testing
- [177Lu]Lu-PSMA-617, Best supportive/best standard of care (BS/BSOC), 68Ga-PSMA-11
- Where
- 17 sites in China
- Volunteers
- 62 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Docetaxel, Doxorubicin, and Prednisone in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy, such as docetaxel, doxorubicin, and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00416533
- Testing
- docetaxel, doxorubicin hydrochloride, prednisone
- Volunteers
- 47 people
- Sponsor
- Wake Forest University Health Sciences
Castration Resistant Prostate Cancer (CRPC)
A Study to Determine Enzalutamide Long-term Safety and Efficacy After Anti-androgen Therapy for CRPC
This is a prospective observational study to evaluate effectiveness and safety of Enzalutamide for Castration Resistant Prostate Cancer (CRPC) patients who decided to administer Enzalutamide after anti-androgen therapy.
- Trial name
- DELC (NCT02669147)
- Volunteers
- 160 people
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Prostate Cancer
Contrast Enhanced Transrectal Ultrasonography (TRUS) to Assess Prostatic Vascularity After Radiotherapy (XRT)
Solid tumors, including prostate cancer, commonly exhibit tumor-associated neovascularity (growth of new blood vessels to feed the tumor) with increased microvessel density.
- Trial name
- NCT00635167
- Testing
- Contrast Enhanced-Transrectal Ultrasound
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Prostate Cancer
Comparison of PSMA-based 18F-DCFPyL PET/CT to Conventional Imaging in the Evaluation of Patients With Castration-Resistant Prostate Cancer
We intend to validate 18F-DCFPyL for imaging patients with metastatic, castrate-resistant PCa (CRPC), so that it may be used to full advantage in supporting existing and emerging therapies for a spectrum of patients suffering…
- Trial name
- NCT02856100
- Testing
- 18F DCFPyL- Radiopharmaceutical
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Evaluating the Effect of a Decision Aid on Shared Decision Making for Prostate Cancer Screening
Decision-aids are tools to educate patients on a given topic so that they may better participate in shared-decision making in their health care.
- Trial name
- NCT01484665
- Testing
- PROCASE Decision-Aid
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Hormone-refractory Prostate Cancer
Analyze the Predictive Value of Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Prostate Cancer
Prostate cancer is the most common non-skin tumor diagnosed in men and the second leading cause of cancer death in men in Western countries.
- Trial name
- PREMIERE (NCT02288936)
- Testing
- Enzalutamide
- Where
- 16 sites in Spain
- Volunteers
- 98 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Prostate Cancer, Urinary Incontinence
The Effects of Pilates in Muscle Strength of the Pelvic Floor as Treatment of Post Prostatectomy Urinary Incontinence
The purpose of this study is to compare the efficacy between a Pilates exercise program and a Pelvic Floor Muscle Training (PFMT) protocol combined with anal electrical stimulation (AES) in muscular pressure strength of the…
- Trial name
- NCT02645136
- Testing
- Pilates, PFMT and AES, Control
- Volunteers
- 115 people
- Sponsor
- Universidade Estadual de Londrina
Prostate Cancer
Quantification of Respiratory-induced Prostate Motion
Patient anatomy and position during the course of radiation therapy can vary from those used for treatment planning; a function of patient movement, uncertainty in positioning system, and organ motion.
- Trial name
- NCT00980993
- Where
- United States
- Sponsor
- Oregon Health and Science University
Sedentary Lifestyle
Adaptation of an eHealth (Web-application) Platform for Delivery of a Sedentary Behavior Intervention Among Prostate Cancer Patients
The overall objective of this study is to adapt and refine an existing eHealth (web-application/web-app/app) platform designed to promote spontaneous movement (reducing sedentary behavior) among older adults, to men with prostate…
- Trial name
- NCT03740035
- Testing
- eHealth for Sedentary Behavior
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Wake Forest University Health Sciences
Prostate Cancer
Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer
The purpose of this research study is to determine the safety of giving ketoconazole, hydrocortisone and dutasteride (KHAD) with lapatinib.
- Trial name
- KHLAD (NCT00953576)
- Testing
- ketoconazole, hydrocortisone, dutasteride
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer
Retrospective, Non-interventional Study of Depo-Eligard®.
Study will evaluate the real-world effectiveness of Depo-Eligard® after six months of treatment
- Trial name
- OCT (NCT00811876)
- Testing
- Data Collection on Depo-Eligard exposure
- Where
- 23 sites in Belgium
- Volunteers
- 140 people
- Sponsor
- Astellas Pharma Inc
Over-Active Bladder
VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate
The purpose of this study is to determine if Vesicare (Solifenacin succinate) is effective in treating over-active bladder symptoms during radiation therapy of the prostate.
- Trial name
- NCT01777217
- Testing
- Solifenacin succinate
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Advanced Research Network
Prostate Cancer
Genetic Counseling Processes and Outcomes Among Males With Prostate Cancer (ProGen)
This randomized controlled trial aims to evaluate the impact of pre-test video education and post-test genetic counseling as compared to in-person pre-test genetic counseling in males with advanced prostate cancer.
- Trial name
- ProGen (NCT03328091)
- Testing
- Traditional pre-test genetic counseling, Pre-test video education
- Where
- 3 sites in United States
- Volunteers
- 662 people
- Sponsor
- Dana-Farber Cancer Institute
Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC)
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer
- Trial name
- NCT06943521
- Testing
- MT-4561
- Where
- 6 sites in United States, Japan
- Volunteers
- 27 people
- Sponsor
- Tanabe Pharma America, Inc.
Malignant Prostate Neoplasm
Daily Adaptive Post-Prostatectomy With Stereotactic Ablative Radiotherapy in Patients With Prostate Cancer
This clinical trial evaluates the feasibility, safety, and tolerability of stereotactic ablative radiotherapy (SABR) using daily adaptive radiation techniques to the prostate fossa and/or pelvic lymph nodes in patients with…
- Trial name
- DAPPER (NCT05830838)
- Testing
- Computed Tomography, Image-Guided Adaptive Radiation Therapy, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Metastatic Castration-Resistant Prostate Cancer
A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy
The purpose of this study is to evaluate the percentage of participants achieving prostate-specific antigen (PSA) response by 12 weeks of therapy from baseline according to Prostate Cancer Clinical Trials Working Group (PCWG2)…
- Trial name
- NCT02405858
- Testing
- Abiraterone Acetate, Prednisolone
- Where
- 14 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Janssen Pharmaceutical K.K.
Prostate Cancer (Adenocarcinoma), Erectile Abnormalities
PRIAPUS-PCa Study: Stereotactic Body Radiation Therapy (SBRT) and Androgen Deprivation Therapy (ADT) Impact on Sexual Function on Men With Unfavorable Intermediate Risk Prostate Cancer
This study looks at how combined radiation and hormone therapy affects sexual function in men with a specific type of prostate cancer, before and after treatment.
- Conditions
- Prostate Cancer (Adenocarcinoma), Erectile Abnormalities, Sexual Dysfunction Male
- Trial name
- PRIAPUS-PCa (NCT07460726)
- Testing
- SBRT combined with ADT
- Where
- Canada
- Volunteers
- 130 people
- Sponsor
- CancerCare Manitoba
Prostate Cancer
Towards Optimal Prescription of Chemotherapy in Prostate Cancer
This study will examine the impact of modern treatments for metastatic Castrate Resistant Prostate Cancer (mCRPC) on several relevant 'geriatric' domains such as daily function, objective physical function, and falls.
- Trial name
- TOPCOP (NCT02512185)
- Where
- 4 sites in Canada
- Volunteers
- 206 people
- Sponsor
- University Health Network, Toronto